ABBV AbbVie Inc.

110.52
-1.11  -1%
Previous Close 111.63
Open 111.2
52 Week Low 62.55
52 Week High 113.41
Market Cap $195,120,177,970
Shares 1,765,473,923
Float 1,764,121,099
Enterprise Value $274,229,177,969
Volume 9,196,049
Av. Daily Volume 8,574,518
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Botox
Neurogenic Detrusor Overactivity
PDUFA
PDUFA
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Upadacitinib
Psoriatic arthritis
PDUFA
PDUFA
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
RINVOQ (upadacitinib)
Active Ankylosing Spondylitis
PDUFA
PDUFA
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Cenicriviroc (CVC)
Nonalcoholic steatohepatitis (NASH)
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
ABBV-951
Parkinson's disease
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Venetoclax - CANOVA
Relapsed or refractory multiple myeloma
Phase 3
Phase 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Risankizumab MOTIVATE
Crohn’s Disease
Phase 3
Phase 3
Phase 3 trial met primary endpoint - January 7, 2021.
Risankizumab KEEPSAKE2
Psoriatic Arthritis
Phase 3
Phase 3
Phase 3 trial met primary endpoint - January 5, 2021.
Imbruvica + Venclexta (CAPTIVATE)
Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma
Phase 2
Phase 2
Phase 2 trial ongoing.
Ibrutinib in combination with prednisone
Chronic Graft Versus Host Disease
Phase 3
Phase 3
Phase 3 trial ongoing.
Upadacitinib - U-ACHIEVE
Ulcerative colitis
Phase 3
Phase 3
Phase 3 trial met primary and secondary endpoints - December 9, 2020.
Depatuxizumab mafodotin ABT-414
Glioblastoma (rGBM)
Phase 3
Phase 3
Phase 3 trial did not meet primary endpoint at interim analysis - May 17, 2019.
AGN-190584
Presbyopia
Phase 3
Phase 3
Phase 3 trial met primary endpoint - October 28, 2020.
Upadacitinib
Atopic Dermatitis
sNDA Filing
sNDA Filing
Regulatory filing announced October 19, 2020.
Venclexta (VIALE-A)
Acute Myeloid Leukemia (AML)
Approved
Approved
FDA approval announced October 16, 2020.
ABT-494
Psoriatic Arthritis
Phase 3
Phase 3
Phase 3 trial to commenced 2017.
Ibrutinib
COVID-19
Phase 2
Phase 2
Phase 2 trial has been initiated.
Cenicriviroc + Otezla (apremilast) + Firazyr (icatibant)
COVID-19 (severe)
Phase 2
Phase 2
Phase 2 trial initiation announced August 3, 2020.
ATOGEPANT
Chronic migraine
Phase 3
Phase 3
Phase 3 trial met primary endpoint - July 29, 2020.
Risankizumab vs secukinumab
Plaque psoriasis
Phase 3
Phase 3
Phase 3 trial met primary endpoint - January 14, 2020.
Upadacitinib
Atopic dermatitis
Phase 3
Phase 3
Phase 3 data met co-primary endpoints - June 18, 2020. Second Phase 3 trial also met primary endpoint - July 21, 2020.
ABICIPAR
Age-related macular degeneration (AMD)
CRL
CRL
CRL issued June 26, 2020.
Botox
Forehead lines
Approved
Approved
Approval (third indication) announced October 3, 2017.
JUVÉDERM VOLUMA
Augmentation of the chin region
Approved
Approved
FDA Approval announced June 15, 2020.
Elagolix
Uterine Fibroids
Approved
Approved
FDA approval announced May 29, 2020.
Oxymetazoline HCl cream 1.0%
Facial Erythema (Redness) Associated with Rosacea
Approved
Approved
Approved January 19, 2017.
MVASITM (bevacizumab-awwb)
Biosimilar candidate to Avastin (bevacizumab)
Approved
Approved
Approved September 14, 2017.
Botox
Lower limb spasticity
Approved
Approved
FDA Approval announced October 24, 2019.
Ubrogepant
Migraine
Approved
Approved
FDA Approval announced December 23, 2019.
Botox
Upper limb spasticity
Approved
Approved
FDA Approval announced June 21, 2019.
Juvéderm VOLUMA
Mid-Face Injection Via Cannula
Approved
Approved
FDA Approval announced September 3, 2019.
IMBRUVICA (ibrutinib) and rituximab
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Approved
Approved
FDA Approval announced April 21, 2020.
Rova-T (MERU)
First-line Small Cell Lung Cancer
Phase 3
Phase 3
Phase 3 trial demonstrated no survival benefit at interim analysis - October 29, 2019.
Risankizumab ( LIMMITLESS )
Psoriasis
Phase 3
Phase 3
Phase 3 data presented at EADV October 10, 2019.
Veliparib
Ovarian cancer
Phase 3
Phase 3
Phase 3 presentation at ESMO 28 September 2019.
ABT-494 upadacitinib
Rheumatoid arthritis
Approved
Approved
FDA Approval announced August 16, 2019.
ABBV-8E12
Alzheimer's disease
Phase 2
Phase 2
Phase 2 initiation announced January 25, 2017.
Rova-T (TAHOE)
Second-line Small Cell Lung Cancer
Phase 3
Phase 3
Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018.
Venetoclax and obinutuzumab
Chronic lymphocytic leukemia
sNDA Filing
sNDA Filing
sNDA filing announced June 4, 2019.
Venetoclax and obinutuzumab
Chronic Lymphocytic Leukemia
Phase 3
Phase 3
FDA approval announced May 15, 2019.
Risankizumab
Psoriasis
Approved
Approved
FDA approval announced April 23, 2019.
Venclexta BELLINI
Multiple myeloma
Phase 3
Phase 3
Phase 3 primary endpoint met.
Imbruvica and Gazyva - iLLUMINATE
Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)
Approved
Approved
FDA approval announced January 28, 2019.
Ibrutinib (Imbruvica)
Pancreatic cancer
Phase 3
Phase 3
Phase 3 primary endpoint not met (PFS/OS).
Venclexta
First line unfit AML
Approved
Approved
FDA approval announced November 21, 2018.
IMBRUVICA (ibrutinib)
Waldenström’s Macroglobulinemia
Approved
Approved
FDA approval announced August 27, 2018.
Elagolix
Endometriosis
Approved
Approved
FDA approval announced July 24, 2018.
IMBRUVICA (ibrutinib)
Diffuse large B-cell lymphoma (DLBCL)
Phase 3
Phase 3
Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
Venclexta (MURANO)
Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)
Approved
Approved
Approval announced June 11, 2018.
Rova-T (TRINITY)
Third-line Small Cell Lung Cancer
Phase 2
Phase 2
Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
Imbruvica
Second-line Chronic graft-versus-host disease (GVHD)
Approved
Approved
Approval announced August 2, 2017.
Glecaprevir/Pibrentasvir (G/P)
Hepatitis C virus (HCV)
Approved
Approved
Approval announced August 3, 2017.
Imbruvica
Marginal zone lymphoma
Approved
Approved
sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
IMBRUVICA
Waldenström’s Macroglobulinemia
Approved
Approved
Approved January 29, 2015 - PCYC
VIEKIRA PAK
HCV - genotype 1
Approved
Approved
Approved December 19, 2014.
Imbruvica
Deletion 17p
Approved
Approved
Approved July 19, 2014.
Imbruvica
Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy
Approved
Approved
Approved February 12, 2014.
Ibrutinib
Relapsed or refractory MCL mantle cell lymphoma
Approved
Approved
Approved November 13, 2013.
Veliparib
Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC)
Phase 3
Phase 3
Phase 3 trial did not meet primary endpoints - April 19, 2017.

Latest News

  1. NORTH CHICAGO, Ill., Jan. 15, 2021 /PRNewswire/ -- Allergan Aesthetics and Allergan, an AbbVie company (NYSE:ABBV), announced today that scientific and clinical experts in the field of neurotoxins will present results from 16 abstracts spanning pre-clinical and clinical studies evaluating key safety and efficacy of BOTOX® (onabotulinumtoxinA) across multiple therapeutic and cosmetic indications. Data includes long-term immunogenicity rates across 10 therapeutic and aesthetic indications, analyses from the Adult Spasticity International Registry (ASPIRE) study and Cervical Dystonia Patient Registry for BOTOX® Efficacy (CD-PROBE), reviewing adherence to onabotulinumtoxinA treatment in patients with spasticity and efficacy and tolerability in patients…

    NORTH CHICAGO, Ill., Jan. 15, 2021 /PRNewswire/ -- Allergan Aesthetics and Allergan, an AbbVie company (NYSE:ABBV), announced today that scientific and clinical experts in the field of neurotoxins will present results from 16 abstracts spanning pre-clinical and clinical studies evaluating key safety and efficacy of BOTOX® (onabotulinumtoxinA) across multiple therapeutic and cosmetic indications. Data includes long-term immunogenicity rates across 10 therapeutic and aesthetic indications, analyses from the Adult Spasticity International Registry (ASPIRE) study and Cervical Dystonia Patient Registry for BOTOX® Efficacy (CD-PROBE), reviewing adherence to onabotulinumtoxinA treatment in patients with spasticity and efficacy and tolerability in patients with cervical dystonia, respectively. Also to be presented are data on incontinence product use and associated costs in patients with overactive bladder treated with onabotulinumtoxinA. Additionally, results from a randomized controlled clinical trial on the efficacy and safety of three active doses of onabotulinumtoxinA for the treatment of neurogenic detrusor overactivity in children and findings from a study on the safety, pharmacodynamic response and treatment satisfaction, with increasing doses of onabotulinumtoxinA in patients with moderate to severe dynamic glabellar lines will be presented. These data will be presented at the TOXINS 2021 Virtual Conference, organized by The International Neurotoxin Association (INA), January 16-17.

    "We continue to be deeply committed to advancing research of neurotoxins and are pleased to be able to share the depth and breadth of our latest data on BOTOX® and BOTOX® Cosmetic at the TOXINS 2021 Virtual Conference," said Mitchell F. Brin, M.D., Senior Vice President, Chief Scientific Officer, BOTOX® & Neurotoxins, AbbVie. "With over 30 years in the neurotoxin space, we are excited to further build on this heritage as part of AbbVie. It allows us to support health professionals in meeting the individual needs of patients around the world on an even greater scale, both now and in the future."

    The abstracts are expected to be published online in a supplement of the journal Toxicon on January 16, 2021 with open access for six months after the conference. They will also be presented virtually over the course of the two-day conference.

    The TOXINS 2021 Virtual Poster Hall opens on January 16 and will remain open to conference attendees for 60 days post-conference. AbbVie abstracts being presented at the conference are outlined below.

    Adherence to OnabotulinumtoxinA Treatment in Patients with Spasticity from the ASPIRE Study

    Sustained Efficacy and Tolerability of OnabotulinumtoxinA in Naive and Non-naive Patients with Cervical Dystonia: Preliminary Completer Analysis from CD-PROBE

    Reduction in Incontinence Product Use and Associated Cost Savings After OnabotulinumtoxinA Treatment in Patients with Overactive Bladder

    Lower Limb Injections of OnabotulinumtoxinA: Improvement in Gait and Treatment Goal Achievement in Pediatric Patients with Cerebral Palsy

    Efficacy and Safety of an Alternative OnabotulinumtoxinA Injection Paradigm for Overactive Bladder: Final Double-Blind and Open-Label Results in Female Patients

    Efficacy and Safety of Three Active Doses of OnabotulinumtoxinA for the Treatment of Neurogenic Detrusor Overactivity in Children: Results of a Randomized Controlled Clinical Trial

    Real-life Use of OnabotulinumtoxinA for Symptom Relief in Patients with Chronic Migraine: REPOSE Study German Population

    Safety, Pharmacodynamic Response, and Treatment Satisfaction with OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects with Moderate to Severe Dynamic Glabellar Lines

    Safety and Efficacy of OnabotulinumtoxinA for Treatment of Masseter Muscle Hypertrophy: Results from a Phase 2 Dose-Escalation Study

    Pregnancy Outcomes Following Exposure to OnabotulinumtoxinA Update: 29 Years of Safety Observation

    OnabotulinumtoxinA (OnabotA) Exhibits Greater Efficacy Compared with Purified Botulinum Neurotoxin A (BoNT/A-150 kDa) in Peripheral Pain Models

    Greater Biological Activity of OnabotulinumtoxinA and Non-interchangeability with Vacuum-Dried PrabotulinumtoxinA

    Botulax displays lower enzymatic activity when compared to onabotulinumtoxinA in a light chain activity assay

    A Cell-Penetrating Peptide (CPP) Did Not Decrease 150-kDa BoNT/A Toxin Adsorption to Surfaces or Increase Toxin Potency or Duration in a Prototype Formulation

    Neutralizing Antibody Conversion with OnabotulinumtoxinA from Global Studies Across Multiple Indications in Nearly 30,000 Patient Records: A Meta-Analysis

    Engineering SNAP23 Specificity into the Highly Selective Clostridium Botulinum Protease

    About BOTOX® 

    BOTOX® (onabotulinumtoxinA) U.S. Important Information

    IMPORTANT SAFETY INFORMATION

    BOTOX® and BOTOX® Cosmetic may cause serious side effects that can be life threatening.  Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® or

    BOTOX® Cosmetic:

    • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life.  You are at the highest risk if these problems are pre-existing before injection.  Swallowing problems may last for several months
    • Spread of toxin effects.  The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing

    There has not been a confirmed serious case of spread of toxin effect away from the injection site when BOTOX® has been used at the recommended dose to treat chronic migraine, severe underarm sweating, blepharospasm, strabismus, or when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow's feet lines, and/or forehead lines.

    Indications

    BOTOX® is a prescription medicine that is injected into specific muscles and used:

    • To treat overactive bladder symptoms such as a strong need to urinate with leaking or wetting accidents (urge urinary incontinence), a strong need to urinate right away (urgency), and urinating often (frequency) in adults 18 years and older when another type of medicine (anticholinergic) does not work well enough or cannot be taken
    • To treat leakage of urine (incontinence) in adults 18 years and older with overactive bladder caused by a neurologic disease who still have leakage or cannot tolerate the side effects after trying an anticholinergic medication
    • To prevent headaches in adults with chronic migraine who have 15 or more days each month with headache lasting 4 or more hours each day in people 18 years or older
    • To treat increased muscle stiffness in people 2 years of age and older with spasticity
    • To treat the abnormal head position and neck pain that happens with cervical dystonia (CD) in people 16 years and older
    • To treat certain types of eye muscle problems (strabismus) or abnormal spasm of the eyelids (blepharospasm) in people 12 years and older

    BOTOX® is also injected into the skin to treat the symptoms of severe underarm sweating (severe primary axillary hyperhidrosis) when medicines used on the skin (topical) do not work well enough in people 18 years and older.

    BOTOX® Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults.

    It is not known whether BOTOX® and BOTOX® Cosmetic are safe or effective to prevent headaches in patients with migraine who have 14 or fewer headache days each month (episodic migraine).

    BOTOX® has not been shown to help people perform task-specific functions with their upper limbs or increase movement in joints that are permanently fixed in position by stiff muscles.

    It is not known whether BOTOX® and BOTOX® Cosmetic are safe or effective for severe sweating anywhere other than your armpits.

    It is not known if BOTOX® Cosmetic is safe or effective for use more than 1 time every 3 months.

    IMPORTANT SAFETY INFORMATION (continued)

    BOTOX® and BOTOX® Cosmetic may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of taking BOTOX® or BOTOX® Cosmetic.  If this happens, do not drive, operate machinery, or do other dangerous activities.

    Do not receive BOTOX® or BOTOX® Cosmetic if you: are allergic to any of its ingredients (see Medication Guide for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc® (rimabotulinumtoxinB), Dysport® (abobotulinumtoxinA), or Xeomin® (incobotulinumtoxinA); have a skin infection at the planned injection site.

    Do not receive BOTOX® for the treatment of urinary incontinence if you: have a urinary tract infection (UTI) or cannot empty your bladder on your own and are not routinely catheterizing.  Due to the risk of urinary retention (not being able to empty the bladder), only patients who are willing and able to initiate catheterization post-treatment, if required, should be considered for treatment.

    Patients treated for overactive bladder:

    In clinical trials, 36 of the 552 patients had to self-catheterize for urinary retention following treatment with BOTOX® compared to 2 of the 542 treated with placebo.  The median duration of post-injection catheterization for these patients treated with BOTOX® 100 Units (n = 36) was 63 days (minimum 1 day to maximum 214 days) as compared to a median duration of 11 days (minimum 3 days to maximum 18 days) for patients receiving placebo (n = 2).  Patients with diabetes mellitus treated with BOTOX® were more likely to develop urinary retention than nondiabetics.

    Patients treated for overactive bladder due to neurologic disease:

    In clinical trials, 30.6% of patients (33/108) who were not using clean intermittent catheterization (CIC) prior to injection, required catheterization for urinary retention following treatment with BOTOX® 200 Units as compared to 6.7% of patients (7/104) treated with placebo.  The median duration of post-injection catheterization for these patients treated with BOTOX® 200 Units (n = 33) was 289 days (minimum 1 day to maximum 530 days) as compared to a median duration of 358 days (minimum 2 days to maximum 379 days) for patients receiving placebo (n = 7).  Among patients not using CIC at baseline, those with MS were more likely to require CIC post injection than those with SCI.

    The dose of BOTOX® and BOTOX® Cosmetic is not the same as, or comparable to, any other botulinum toxin product.

    Serious and/or immediate allergic reactions have been reported, including itching, rash, red itchy welts, wheezing, asthma symptoms, dizziness, or feeling faint.  Get medical help right away if you experience symptoms; further injection of BOTOX® or BOTOX® Cosmetic should be discontinued.

    Tell your doctor about all your muscle or nerve conditions, such as amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig's disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects including difficulty swallowing and difficulty breathing from typical doses of BOTOX® or BOTOX® Cosmetic.

    Tell your doctor if you have any breathing-related problems.  Your doctor may monitor you for breathing problems during treatment with BOTOX® for spasticity or for detrusor overactivity associated with a neurologic condition.  The risk of developing lung disease in patients with reduced lung function is increased in patients receiving BOTOX®.

    Cornea problems have been reported.  Cornea (surface of the eye) problems have been reported in some people receiving BOTOX® for their blepharospasm, especially in people with certain nerve disorders.  BOTOX® may cause the eyelids to blink less, which could lead to the surface of the eye being exposed to air more than is usual.  Tell your doctor if you experience any problems with your eyes while receiving BOTOX®.  Your doctor may treat your eyes with drops, ointments, contact lenses, or with an eye patch.

    Bleeding behind the eye has been reported.  Bleeding behind the eyeball has been reported in some people receiving BOTOX® for their Strabismus.  Tell your doctor if you notice any new visual problems while receiving BOTOX®.

    Bronchitis and upper respiratory tract infections (common colds) have been reported. Bronchitis was reported more frequently in adults receiving BOTOX® for upper limb spasticity. Upper respiratory infections were also reported more frequently in adults with prior breathing-related problems with spasticity.  In pediatric patients treated with BOTOX® for upper limb spasticity, upper respiratory tract infections were reported more frequently.  In pediatric patients treated with BOTOX® for lower limb spasticity, upper respiratory tract infections were not reported more frequently than placebo.

    Autonomic dysreflexia in patients treated for overactive bladder due to neurologic disease.  Autonomic dysreflexia associated with intradetrusor injections of BOTOX® could occur in patients treated for detrusor overactivity associated with a neurologic condition and may require prompt medical therapy.  In clinical trials, the incidence of autonomic dysreflexia was greater in patients treated with BOTOX® 200 Units compared with placebo (1.5% versus 0.4%, respectively).

    Tell your doctor about all your medical conditions, including if you: have or have had bleeding problems; have plans to have surgery; had surgery on your face; weakness of forehead muscles; trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; have symptoms of a urinary tract infection (UTI) and are being treated for urinary incontinence (symptoms of a urinary tract infection may include pain or burning with urination, frequent urination, or fever); have problems emptying your bladder on your own and are being treated for urinary incontinence; are pregnant or plan to become pregnant (it is not known if BOTOX® or BOTOX® Cosmetic can harm your unborn baby); are breastfeeding or plan to (it is not known if BOTOX® or BOTOX® Cosmetic passes into breast milk).

    Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.  Using BOTOX® or BOTOX® Cosmetic with certain other medicines may cause serious side effects.  Do not start any new medicines until you have told your doctor that you have received BOTOX® or BOTOX® Cosmetic in the past.

    Tell your doctor if you have received any other botulinum toxin product in the last 4 months; have received injections of botulinum toxin such as Myobloc®, Dysport®, or Xeomin® in the past (tell your doctor exactly which product you received); have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; take aspirin-like products or blood thinners.

    Other side effects of BOTOX® and BOTOX® Cosmetic include: dry mouth, discomfort or pain at the injection site, tiredness, headache, neck pain, eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids, swelling of your eyelids, dry eyes; drooping eyebrows; and upper respiratory tract infection.  In people being treated for urinary incontinence other side effects include urinary tract infection, painful urination, and/or inability to empty your bladder on your own.  If you have difficulty fully emptying your bladder after receiving BOTOX®, you may need to use disposable self-catheters to empty your bladder up to a few times each day until your bladder is able to start emptying again.

    For more information refer to the Medication Guide or talk with your doctor.

    You are encouraged to report negative side effects of prescription drugs to the FDA.  Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

    Please see BOTOX® full Product Information, including Boxed Warning and Medication Guide.

    Please see BOTOX® Cosmetic full Product Information, including Boxed Warning and Medication Guide

    Globally, prescribing information varies; refer to the individual country product label for complete information.

    About Allergan Aesthetics

    Allergan Aesthetics, an AbbVie company, develops, manufactures, and markets a portfolio of leading aesthetics brands and products.  Their aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more.  Their goal is to consistently provide customers worldwide with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. www.AllerganAesthetics.com

    About AbbVie in Neuroscience

    At AbbVie, our commitment to preserve the personhood of those living with neurological and psychiatric disorders is unwavering.  Every challenge in this uncharted territory makes us more determined and drives us harder to discover and deliver solutions for patients, care partners and clinicians.  AbbVie's Neuroscience portfolio consists of approved therapies and a robust pipeline in neurological and psychiatric disorders, including Alzheimer's disease, bipolar disorder and depression, major depressive disorder, migraine, multiple sclerosis, Parkinson's disease, spinal cord injuries, post-stroke spasticity, schizophrenia, and stroke.

    We have a strong investment in neuroscience research, with our Foundational Neuroscience Center in Cambridge, Massachusetts, and our Neuroscience Discovery site in Ludwigshafen, Germany, where our research and resilience in these challenging therapeutic areas is yielding a deeper understanding of the pathophysiology of neurological and psychiatric disorders, and identifying targets for potential disease-modifying therapeutics aimed at making a difference in people's lives.  For more information, please visit www.abbvie.com.

    About AbbVie

    AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow.  We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.  For more information about AbbVie, please visit us at www.abbvie.com.  Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

    Forward-Looking Statements

    Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements.  AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.  Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19.  Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2019 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q.  AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

    Cision View original content:http://www.prnewswire.com/news-releases/allergan-aesthetics-and-allergan-an-abbvie-company-to-present-16-neurotoxin-research-abstracts-across-multiple-therapeutic-and-cosmetic-indications-at-the-toxins-2021-virtual-conference-301208924.html

    SOURCE AbbVie

    View Full Article Hide Full Article
  2. SOUTH SAN FRANCISCO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN217 for the treatment of multiple myeloma. HPN217, a tri-specific T cell activating recombinant protein construct (TriTAC®) targets B-cell maturation antigen (BCMA), a well-validated antigen expressed on malignant multiple myeloma cells. Harpoon has four drug product candidates in clinical development for the treatment of solid and hematologic malignancies based on its proprietary TriTAC platform.

    "Orphan Drug Designation for multiple myeloma represents…

    SOUTH SAN FRANCISCO, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN217 for the treatment of multiple myeloma. HPN217, a tri-specific T cell activating recombinant protein construct (TriTAC®) targets B-cell maturation antigen (BCMA), a well-validated antigen expressed on malignant multiple myeloma cells. Harpoon has four drug product candidates in clinical development for the treatment of solid and hematologic malignancies based on its proprietary TriTAC platform.

    "Orphan Drug Designation for multiple myeloma represents a significant milestone in the development of HPN217 and recognizes its potential to address a significant unmet medical need for the patients suffering from this condition," said Jerry McMahon, Ph.D., President and Chief Executive of Harpoon Therapeutics. "I am pleased with the clinical progress we are making with this program and we are planning to present interim data from the ongoing Phase 1/2 dose escalation trial later this year."

    The FDA's Orphan Drug Designation program provides orphan status to drugs defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases that affect fewer than 200,000 people in the United States. Orphan Drug Designation qualifies the sponsor of the drug for certain development incentives, including tax credits for qualified clinical testing, prescription drug user fee exemptions and seven-year marketing exclusivity upon FDA approval.

    About the Phase 1/2 Trial for HPN217

    In April 2020, Harpoon announced dosing of the first patient with HPN217 (BCMA TriTAC) in a Phase 1/2 clinical trial focused on relapsed/refractory multiple myeloma (RRMM). HPN217 is covered by a global development and option agreement with AbbVie Inc. (NYSE:ABBV). Dose escalation for HPN217 in the Phase 1/2 clinical trial is progressing rapidly. HPN217 has been well tolerated, and no DLTs had been observed as of the most recent December 1, 2020 data cutoff date. A presentation of interim data is anticipated in 2021, with initiation of a dose expansion cohort in the second half of 2021.

    For additional information about the trial, please visit clinicaltrials.gov using the identifier NCT04184050.

    About Harpoon Therapeutics

    Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient's own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and is in a Phase 1/2 trial for small cell lung cancer and other DLL3-associated tumors. Harpoon has also developed a proprietary ProTriTAC™ platform, which applies a prodrug concept to its TriTAC platform to create a therapeutic T cell engager that remains inactive until it reaches the tumor. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.

    Cautionary Note on Forward-looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "target," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics' expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics' clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, scope and anticipated results of clinical trials, the timing of the presentation of data, the association of data with potential treatment outcomes, the development and advancement of product candidates, the timing of development milestones for product candidates, and the anticipated potential impacts to Harpoon Therapeutics' business from the ongoing COVID-19 pandemic. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause Harpoon Therapeutics' actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics' filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

    Contacts:

    Harpoon Therapeutics, Inc.

    Georgia Erbez

    Chief Financial Officer

    650-443-7400

    Westwicke ICR

    Robert H. Uhl

    Managing Director

    858-356-5932



    Primary Logo

    View Full Article Hide Full Article
  3. IRVINE, Calif., Jan. 12, 2021 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE:ABBV), announced that it has entered into a warrant agreement with Cypris Medical, a privately held, medical device company based in Chicago. Following the completion of a clinical trial to be initiated in 2021, Allergan Aesthetics will have the right to exercise an option to acquire Cypris Medical, including the company's Xact device. The planned clinical trial will evaluate the safety and effectiveness of Xact in treating midface descent as well as for neck lifts.

    Replacing the scalpel, Xact is designed to allow for lifting and suturing of the superficial muscular aponeurotic system (SMAS), the same tissue mobilized in a facelift, but in a minimally-invasive…

    IRVINE, Calif., Jan. 12, 2021 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE:ABBV), announced that it has entered into a warrant agreement with Cypris Medical, a privately held, medical device company based in Chicago. Following the completion of a clinical trial to be initiated in 2021, Allergan Aesthetics will have the right to exercise an option to acquire Cypris Medical, including the company's Xact device. The planned clinical trial will evaluate the safety and effectiveness of Xact in treating midface descent as well as for neck lifts.

    Replacing the scalpel, Xact is designed to allow for lifting and suturing of the superficial muscular aponeurotic system (SMAS), the same tissue mobilized in a facelift, but in a minimally-invasive manner. The innovative technology intends to provide patients surgery-like results in the office with little to no downtime.

    "As a global leader in aesthetics, we are proud to support the research of an innovative device that complements our iconic portfolio of non-invasive treatment options like Botox Cosmetic and our Juvéderm Collection of Fillers," says Carrie Strom, SVP AbbVie and President, Global Allergan Aesthetics. "We know there is continued unmet need for minimally-invasive procedures for midface descent, and Xact affords us the ability to create a new alternative for our customers so they can continue to offer leading-edge treatments to patients."  

    "As the market leader in facial aesthetics, Allergan Aesthetics is the ideal partner to lead the advancement and continued development of Xact," says Dan Holton, President and CEO, Cypris Medical. "We share the same vision with respect to product safety, efficacy and data-driven innovation which allow us to offer plastic surgeons and patients new options for aesthetic medicine."

    About Allergan Aesthetics

    At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.AllerganAesthetics.com.

    About AbbVie

    AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on TwitterFacebookInstagramYouTube and LinkedIn.

    Forward-Looking Statements

    Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2019 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

    (PRNewsfoto/AbbVie)

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/allergan-aesthetics-enters-into-option-to-acquire-cypris-medical-301206886.html

    SOURCE AbbVie

    View Full Article Hide Full Article
  4. NORTH CHICAGO, Ill., Jan. 12, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its fourth-quarter and full-year 2020 financial results on Wednesday, February 3, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

    About AbbVie

    AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology…

    NORTH CHICAGO, Ill., Jan. 12, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV) will announce its fourth-quarter and full-year 2020 financial results on Wednesday, February 3, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

    About AbbVie

    AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

    Cision View original content:http://www.prnewswire.com/news-releases/abbvie-to-host-fourth-quarter-and-full-year-2020-earnings-conference-call-301205553.html

    SOURCE AbbVie

    View Full Article Hide Full Article
  5. Dragonfly to receive payment for the first Opt-In from AbbVie as part of a multi-target collaboration launched just over 1 year ago.

    WALTHAM, Mass., Jan. 12, 2021 /PRNewswire/ -- Dragonfly Therapeutics ("Dragonfly"), a biotechnology company developing novel immunotherapies that harness the innate immune system to treat disease, today announced that AbbVie (NYSE:ABBV), has licensed its first TriNKET™ drug candidate from Dragonfly, part of a multi-target collaboration initiated in November 2019 designed to advance a number of Dragonfly's novel NK cell engager-based immunotherapies for autoimmune and oncology indications.

    "AbbVie is committed to delivering improved treatment options to our patients" said Tom Hudson, M.D. Senior Vice President, R&D and Chief Scientific Officer at AbbVie.  "The collaboration with Dragonfly has been remarkable. Working together, the teams have made rapid progress to develop this first TriNKET in record time."

    "AbbVie is a global leader in treating immune-mediated diseases" said Bill Haney, co-founder and chief executive officer of Dragonfly, "they are a terrific partner and this opt-in, so soon after launching our collaboration, is a great vote of confidence. We look forward to continued success and rapid progress with the AbbVie team to advance new treatment options for patients."

    The opt-in grants AbbVie exclusive worldwide intellectual property rights to develop and commercialize products directed to this first specific target, developed using Dragonfly's TriNKET™ technology platform. Dragonfly will receive an opt-in payment, as well as potential future development milestone payments and royalties from the sales of any commercialized candidates.

    About Dragonfly

    Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel TriNKET™ technology to harness the body's innate immune system to bring breakthrough cancer treatments to patients.

    For more information visit:

    www.dragonflytx.com

    https://www.linkedin.com/company/dragonfly-therapeutics-inc

    https://twitter.com/dragonflytx

    DRAGONFLY MEDIA CONTACT:

    Anne Deconinck |

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/dragonfly-therapeutics-announces-abbvie-opt-in-of-trinket-immunotherapy-drug-candidate-301205963.html

    SOURCE Dragonfly Therapeutics, Inc.

    View Full Article Hide Full Article
View All AbbVie Inc. News